New therapies for prostate cancer?

Commentary to: VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells Lymor Ringer, Paul Sirajuddin, Venkata Mahidhar Yenugonda, Anup Ghosh, Kyle Divito, Valerie Trabosh, Yesha Patel, Amanda Brophy, Scott Grindrod, Michael P. Lisanti, Mil...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2010-08, Vol.10 (4), p.326-328
Main Authors: Tanowitz, Herbert B., Machado, Fabiana S.
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - pharmacology
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Binding
Biology
Bioscience
Calcium
Cancer
Cell
Cell Cycle - drug effects
Cell Cycle Proteins - metabolism
Cell Proliferation - drug effects
Cycle
Cyclin-Dependent Kinases - antagonists & inhibitors
Dansyl Compounds - pharmacology
Humans
Landes
Male
Organogenesis
Prostatic Neoplasms - drug therapy
Proteins
Receptor, ErbB-2 - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Commentary to: VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells Lymor Ringer, Paul Sirajuddin, Venkata Mahidhar Yenugonda, Anup Ghosh, Kyle Divito, Valerie Trabosh, Yesha Patel, Amanda Brophy, Scott Grindrod, Michael P. Lisanti, Milton L. Brown, Maria Laura Avantaggiati, Olga C. Rodriguez and Chris Albanese
ISSN:1538-4047
1555-8576
DOI:10.4161/cbt.10.4.13102